Skip to main content
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. — Investor Relations & Filings

Ticker · TCRX ISIN · US89854M1018 US Professional, scientific and technical activities
Open in API
Filings indexed 310 across all filing types
Latest filing 2023-04-25 Annual Report
Country US United States of America
Listing US TCRX

About TScan Therapeutics, Inc.

https://www.tscan.com

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of cancer. The company's approach is centered on discovering highly effective, naturally occurring TCRs and using them to genetically reprogram T cells. This strategy aims to harness the power of the human immune system to deliver safe and effective immunotherapies to patients.

Recent filings

Filing Released Lang Actions
ARS
Annual Report
2023-04-25 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement related to shareholder voting matters for an annual meeting. It includes information about voting on director elections and auditor ratification, typical content for proxy solicitation materials. The document is titled 'Proxy Statement' and references the Annual Meeting date and voting instructions. It does not contain financial statements or detailed financial analysis, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a Remuneration Information report (DEF 14A) despite the code similarity because the document is a proxy statement, not solely executive compensation details. The document is definitive additional materials to the proxy statement, which fits the Proxy Solicitation & Information Statement category (PSI). The document length is under 5,000 characters, but it contains substantive proxy voting information, not just an announcement of a report publication, so it is not RPA or RNS. Therefore, the best classification is PSI with high confidence.
2023-04-25 English
DEF 14A
Proxy Solicitation & Information Statement
2023-04-25 English
FORM 4 SUBMISSION
Director's Dealing
2023-04-10 English
FORM 3 SUBMISSION
Director's Dealing
2023-04-10 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 6, 2023, by TScan Therapeutics, Inc. The key content is the appointment of a new director, Barbara Klencke, M.D., to the Board of Directors. It details her term, compensation, and related arrangements. There is no financial data or report content, only a management change announcement. This fits the category of Board/Management Information (MANG). The document length is 6735 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the classification is MANG with high confidence.
2023-04-10 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.